The negative adjuvant TKI predictor, RB1 alterations, combined RB1 mutations and RB1 CN loss, since they were functionally similar and both presented marginal significance of treatment interaction due to small sample size of each category (Supplementary Table 3 ).
← all excerpts
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.
1
—
—